CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Letermovir

乐特莫韦 杂质对照品Letermovir Impurities

28 个杂质条目28 impurity entries

本页汇总 乐特莫韦 的 28 个杂质对照品条目。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 28 impurity reference standards of Letermovir. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 乐特莫韦(Letermovir)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesIsolation, synthesis and identification of degraded impurities in Letermovir
    Journal of pharmaceutical and biomedical analysis · 2023 · Chai Y et al.  ·  PMID 37703644  ·  DOI
  2. 分析方法Analytical MethodsDevelopment and Full Validation of a Bioanalytical Method for Quantifying Letermovir in Human Plasma Using Ultra-Performance Liquid Chromatography Coupled with Mass Spectrometry
    Chemical & pharmaceutical bulletin · 2021 · Belabbas T et al.  ·  PMID 34193713  ·  DOI
  3. 分析方法Analytical MethodsQuantification of letermovir in human serum using high-performance liquid chromatography with diode array detection
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2020 · Isberner N et al.  ·  PMID 33126068  ·  DOI
  4. 分析方法Analytical MethodsHPLC Determination of Enantiomeric Purity of Letermovir Based on CHIRALPAK AD
    Journal of chromatographic science · 2016 · Zhang T et al.  ·  PMID 27048643  ·  DOI

合成路线参考Reported synthetic routes

以下为公开文献中报道的合成方法(题录信息)。标题多已点明关键反应,可据此查阅原文了解完整路线与工艺条件。Published synthetic approaches. Titles usually name the key transformation; consult the original articles for full routes.

  • 合成方法SynthesisAsymmetric Hydrogen Bonding Catalysis for the Synthesis of Dihydroquinazoline-Containing Antiviral, Letermovir
    Journal of the American Chemical Society · 2017 · Chung CK et al.  ·  PMID 28737937  ·  DOI

乐特莫韦 —— 原料药与杂质对照品Letermovir — drug substance & impurities

共 29 个条目(含原料药本体)29 items incl. the drug substance
Letermovir structure
原料药 APIAPI
乐特莫韦Letermovir
Letermovir
CAS No.917389-32-3
Chemical FormulaC29H28F4N4O4
Purity>95%询价On request
10mg25mg50mg100mg
Letermovir Impurity 2 structure
2
乐特莫韦杂质2Letermovir Impurity 2
Letermovir Impurity 2
CAS No.917389-29-8
Chemical FormulaC30H30F4N4O4
Purity>95%询价On request
10mg25mg50mg100mg
Letermovir Impurity 6 structure
6
乐特莫韦杂质6Letermovir Impurity 6
Letermovir Impurity 6
CAS No.917389-37-8
Chemical FormulaC29H28F4N4O4
Purity>95%询价On request
10mg25mg50mg100mg
Letermovir Impurity 11 structure
11
乐特莫韦杂质11Letermovir Impurity 11
Letermovir Impurity 11
CAS No.2991059-69-7
Chemical FormulaC18H14F4N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Letermovir Impurity 19 structure
19
乐特莫韦杂质19Letermovir Impurity 19
Letermovir Impurity 19
CAS No.654-83-1
Chemical FormulaC8H8F3NO
Purity>95%询价On request
10mg25mg50mg100mg
Letermovir Impurity 20 structure
20
乐特莫韦杂质20Letermovir Impurity 20
Letermovir Impurity 20
CAS No.917389-34-5
Chemical FormulaC30H30F4N4O4
Purity>95%询价On request
10mg25mg50mg100mg
Letermovir Impurity 26 structure
26
乐特莫韦杂质26Letermovir Impurity 26
Letermovir Impurity 26
CAS No.2991059-71-1
Chemical FormulaC29H28F4N4O5
Purity>95%询价On request
10mg25mg50mg100mg
Letermovir Impurity 30 structure
30
乐特莫韦杂质30Letermovir Impurity 30
Letermovir Impurity 30
CAS No.2758792-73-1
Chemical FormulaC18H14F4N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Letermovir Impurity 31 structure
31
乐特莫韦杂质31Letermovir Impurity 31
Letermovir Impurity 31
CAS No.917389-21-0
Chemical FormulaC19H16F4N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Letermovir Impurity 33 structure
33
乐特莫韦杂质33Letermovir Impurity 33
Letermovir Impurity 33
CAS No.2872586-94-0
Chemical FormulaC32H34F4N4O4
Purity>95%询价On request
10mg25mg50mg100mg
Letermovir Impurity 35 structure
35
乐特莫韦杂质35Letermovir Impurity 35
Letermovir Impurity 35
CAS No.884340-24-3
Chemical FormulaC15H12F3NO3
Purity>95%询价On request
10mg25mg50mg100mg
Letermovir Impurity 36 structure
36
乐特莫韦杂质36Letermovir Impurity 36
Letermovir Impurity 36
CAS No.2864441-31-4
Chemical FormulaC23H24F4N4O3
Purity>95%询价On request
10mg25mg50mg100mg
Letermovir Impurity 42 structure
42
乐特莫韦杂质42Letermovir Impurity 42
Letermovir Impurity 42
CAS No.2994645-03-1
Chemical FormulaC29H26F4N4O6
Purity>95%询价On request
10mg25mg50mg100mg
Letermovir Impurity 43 structure
43
乐特莫韦杂质43Letermovir Impurity 43
Letermovir Impurity 43
CAS No.2991299-71-7
Chemical FormulaC29H26F4N4O4
Purity>95%询价On request
10mg25mg50mg100mg
Letermovir Impurity 44 structure
44
乐特莫韦杂质44Letermovir Impurity 44
Letermovir Impurity 44
CAS No.349-65-5
Chemical FormulaC8H8F3NO
Purity>95%询价On request
10mg25mg50mg100mg
Letermovir Impurity 45 structure
45
乐特莫韦杂质45Letermovir Impurity 45
Letermovir Impurity 45
CAS No.349-65-6
Chemical FormulaC27H26F4N4O5
Purity>95%询价On request
10mg25mg50mg100mg
Letermovir Impurity 46 structure
46
乐特莫韦杂质46Letermovir Impurity 46
Letermovir Impurity 46
CAS No.1697691-31-8
Chemical FormulaC10H11BrFNO2
Purity>95%询价On request
10mg25mg50mg100mg
Letermovir Impurity 56 structure
56
乐特莫韦杂质56Letermovir Impurity 56
Letermovir Impurity 56
CAS No.65896-11-9
Chemical FormulaC6H5BrFN
Purity>95%询价On request
10mg25mg50mg100mg
Letermovir Impurity 57 structure
57
乐特莫韦杂质57Letermovir Impurity 57
Letermovir Impurity 57
CAS No.690664-20-1
Chemical FormulaC10H10FNO2
Purity>95%询价On request
10mg25mg50mg100mg
Letermovir Impurity 58 structure
58
乐特莫韦杂质58Letermovir Impurity 58
Letermovir Impurity 58
CAS No.1925371-72-7
Chemical FormulaC13H9BrFNO2
Purity>95%询价On request
10mg25mg50mg100mg
Letermovir Impurity 59 structure
59
乐特莫韦杂质59Letermovir Impurity 59
Letermovir Impurity 59
CAS No.1791412-01-5
Chemical FormulaC17H14FNO4
Purity>95%询价On request
10mg25mg50mg100mg
Letermovir Impurity 60 structure
60
乐特莫韦杂质60Letermovir Impurity 60
Letermovir Impurity 60
CAS No.917389-23-2
Chemical FormulaC15H11BrF4N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Letermovir Impurity 61 structure
61
乐特莫韦杂质61Letermovir Impurity 61
Letermovir Impurity 61
CAS No.917389-26-5
Chemical FormulaC19H16F4N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Letermovir Impurity 62 structure
62
乐特莫韦杂质62Letermovir Impurity 62
Letermovir Impurity 62
CAS No.1779447-21-0
Chemical FormulaC10H10FNO2
Purity>95%询价On request
10mg25mg50mg100mg
Letermovir Impurity 76 structure
76
乐特莫韦杂质76Letermovir Impurity 76
Letermovir Impurity 76
CAS No.124467-23-8
Chemical FormulaC9H5ClFN
Purity>95%询价On request
10mg25mg50mg100mg
Letermovir Impurity 90 structure
90
乐特莫韦杂质90Letermovir Impurity 90
Letermovir Impurity 90
CAS No.59817-32-2
Chemical FormulaC10H14N2O
Purity>95%询价On request
10mg25mg50mg100mg
Letermovir Impurity 92 structure
92
乐特莫韦杂质92Letermovir Impurity 92
Letermovir Impurity 92
CAS No.2758792-75-3
Chemical FormulaC36H34F4N4O4
Purity>95%询价On request
10mg25mg50mg100mg
Letermovir Impurity 93 structure
93
乐特莫韦杂质93Letermovir Impurity 93
Letermovir Impurity 93
CAS No.1229037-03-9
Chemical FormulaC9H5ClFN
Purity>95%询价On request
10mg25mg50mg100mg
Letermovir Impurity 95 structure
95
乐特莫韦杂质95Letermovir Impurity 95
Letermovir Impurity 95
CAS No.67915-02-0
Chemical FormulaC12H16N2O2
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

乐特莫韦 —— 研究文献与合成路线Letermovir — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 乐特莫韦 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Letermovir. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Isolation, synthesis and identification of degraded impurities in Letermovir
    Chai Y, Zhang E, Cai Z, et al. · Journal of pharmaceutical and biomedical analysis · 2023 · 被引 1cited 1

合成路线文献Synthetic-route papers

  1. Integrated Life Cycle Assessment Guides Sustainability in Synthesis: Antiviral Letermovir as a Case Study
    Folkerts S, Hoepfner MG, Guillén-Gosálbez G, et al. · Journal of the American Chemical Society · 2025
  2. Isolation, synthesis and identification of degraded impurities in Letermovir
    Chai Y, Zhang E, Cai Z, et al. · Journal of pharmaceutical and biomedical analysis · 2023
  3. Asymmetric Hydrogen Bonding Catalysis for the Synthesis of Dihydroquinazoline-Containing Antiviral, Letermovir
    Chung CK, Liu Z, Lexa KW, et al. · Journal of the American Chemical Society · 2017

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

乐特莫韦 杂质谱研究要点Letermovir — impurity profiling notes

下面这些是拿到 乐特莫韦 的 29 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 29 impurity entries for Letermovir, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances